Abstract：Abstract: To explore the advantages of serum PIVKA-Ⅱ and AFP detection in the diagnosis of primary hepatocellular carcinoma (HCC), the levels of PIVKA-Ⅱ and AFP in sera of 237 patients were analyzed. The cohort included 115 patients with HBV-related primary HCC, 55 with asymptomatic carriers (AsC), 47 with liver cirrhosis (LC) and 20 with other cancers. The results showed that the levels of serum PIVKA-Ⅱ in HCC group were significantly higher than those in other groups (P<0.05). The sensitivities of AFP, PIVKA-Ⅱ and the two combined were 67.8%, 81.7% and 90.4%, respectively, in diagnosis of HCC, with the areas under the ROC curve being 0.881, 0.945 and 0.962, respectively. The cut-off value of PIVKA-Ⅱ was 32 mAU/mL in diagnosis of HCC. Then, the HCC patients were divided into two groups (the PIVKA-Ⅱ≥40 mAU/mL group and PIVKA-Ⅱ<40 mAU/mL group) based on many studies demonstrating that the cut-off of PIVKA-Ⅱ is 40 mAU/mL. The gender, age, hepatitis B viral load, tumor stage, number of cancer nodules, diameter of tumor mass and antiviral therapy were compared between the two groups. The results showed that hepatitis B viral load was an independent factor affecting the diagnosis of HCC by PIVKA-Ⅱ [OR=1.150, 95% CI (1.022, 1.295), P=0.02]. The level of serum PIVKA-Ⅱ was positively correlated with the diameter of HCC. In addition, the PIVKA-Ⅱ≥32 and AFP<20 group had a larger diameter of tumor mass than the PIVKA-Ⅱ<32 and AFP≥20 group (P=0.035). In conclusion, the serum PIVKA-Ⅱ is superior to the AFP in screening of HCC. The level of serum PIVKA-Ⅱ is positively correlated with the diameter of tumor mass.
引用本文:
侯 帅, 欧阳锡武, 李荣华, 傅 蕾, 符小玉, 郑宜翔, 彭仕芳. 血清PIVKA-Ⅱ与AFP检测在原发性肝细胞癌诊断中的应用[J]. 生命科学研究, 2019, 23(2): 128-134.
HOU Shuai, OUYANG Xi-wu, LI Rong-hua, FU lei, FU Xiao-yu, ZHENG Yi-xiang, PENG Shi-fang. Detection of Serum AFP and PIVKA-Ⅱ Levels for Diagnosis of Primary Hepatocellular Carcinoma. Life Science Research, 2019, 23(2): 128-134.
